19.06.2013
- U.S.-based Royalty Pharma has dropped a hostile bid worth up to $8 billion for Elan, leaving the Irish drugmaker free to seek other suitors having put itself up for sale last week...
18.06.2013
- Elan shareholders approved a share buyback on Monday, meaning U.S.-based Royalty Pharma's hostile bid for the Irish drug firm will lapse unless it succeeds in a legal challenge...
13.06.2013
- When Kelly Martin, a former Merrill Lynch banker with no drug industry experience, took over as CEO of Ireland's Elan in 2003, analysts assumed his mandate was to clean up the...
25.04.2013
- Biogen reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming...
13.08.2012
- Ireland's Elan is to spin off its Neotope drug discovery business platform as a separate public company, making Elan immediately profitable and potentially more appealing as a...
24.07.2012
- Biogen said on Tuesday its second-quarter earnings topped expectations on higher sales of its drugs to treat multiple sclerosis, and the company increased its profit forecast for...
